Articles By Matthew Pillar

  1. Biopharma CMC/Regulatory Relationships In a Global Market 7/27/2022

    Three veteran regulatory/CMC experts dish the good, the bad, and the ugly from the biopharma’s perspective, offering their insight into how you actually can efficiently file and win in multiple global jurisdictions and what mistakes lead to lost time, money, and sanity.

  2. Biopharma Preservation Through Partnership 7/15/2022

    A dearth in biotech capital has put plenty of early stage biopharmas on the rocks this year, threatening the advance of innovative science. Here’s how Silence Therapeutics has leaned into its partnership model to weather the storm.

  3. Bear Biotech Market Dampens Promise Of Live Biotherapeutics 7/8/2022

    New understanding of the gut-brain axis and the microbiome’s modulation of multiple disease states are fueling 30+% CAGR of the live biotherapeutics market, but capital market restrictions are taking a toll on innovators in the space. 

  4. AAV Gene Therapy Takes On Kidney Disease 7/6/2022

    Built on the back of Prof. Moin Saleem’s two decades of cellular-level kidney research, Purespring Therapeutics is reimagining the treatment of kidney diseases that affect nearly a billion people worldwide. The company is preparing a first-of-its-kind AAV gene therapy candidate for the clinic. 

  5. CBER's Peter Marks On Complex Biologics Manufacturing Advances 6/30/2022

    At ISPE’s 2022 Biotechnology Conference In Boston, CBER Director Dr. Peter Marks kicked off three days of programming with reflections on the COVID-19 pandemic as a catalyst to advanced manufacturing in biologics, sharing his vision for industry and the role of the FDA.

  6. The Coming Wave Of Radio(bio)pharmaceuticals 6/13/2022

    Convergent Therapeutics is bullish on the combination of radioisotopes and antibodies to direct radiation directly to cancer cells. As enabling technologies improve on previous failures, CEO, CMO, and co-founder Dr. Philip Kantoff is projecting a new wave of activity in the space among biopharmas big and small.

  7. Virtual Event: Overcome Platform Inefficiencies In mAb Manufacturing 6/7/2022

    Join multifaceted mAb manufacturing experts Gene Lee, CTO at AltruBio and Avril Vermunt, Sr. Director of Manufacturing Sciences & Technology at
    EQRx for a discussion on making mAbs more efficiently in the face of rising costs, growing complexity, and constricting cash runways. 

  8. IPSCs For Democratized Cell Therapy 6/7/2022

    Dr. Daniel Teper and his team at Cytovia Therapeutics have developed a unique combination of candidates designed to improve access to safe and affordable "off-the-shelf" cell therapies. Founded just four years ago, the company is preparing multiple clinical trials of IPSC-derived therapies, which Dr. Teper says lend to a consistent, scalable manufacturing process. 

  9. Differentiation Via Developmental Difficulty 5/27/2022

    By way of its business strategy, Context Therapeutics willfully embraces difficult breast, ovarian, and endometrial oncology development projects. That’s what creates differentiation and value in a therapeutic area that’s desperately lacking both, says VC-turned-CEO Martin Lehr.

  10. Will Anellovirus Vectors Solve Immunogenicity Challenges? 5/20/2022

    Ring Therapeutics is building a first-of-its-kind viral vector platform based on a commensal virus that flies under the immune system’s radar. If its odds-beating CEO is any indication of its success, the company just might beat the immunogenicity challenge.